Talk to your doctor about FASLODEX with palbociclib

FASLODEX is used to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer whose disease has spread to other parts of the body (metastatic) in combination with palbociclib in women with disease progression after hormonal therapy.

Is FASLODEX with palbociclib right for you?

If you…

  • Have received a diagnosis of advanced or metastatic breast cancer and…
  • Your breast cancer is hormone receptor-positive and human epidermal growth factor receptor 2-negative and…
  • Your cancer has spread after previous hormonal therapy…

…then you and your doctor may consider whether FASLODEX with palbociclib is right for you.

Do you have anything in common with the women in the PALOMA-3 study?*

Did your cancer come back or progress during or after prior endocrine therapy?

100% of women in the PALOMA-3 study experienced disease progression during or after prior endocrine therapy.

Have you previously been prescribed chemotherapy?

75% of women in the PALOMA-3 study were previously prescribed chemotherapy.

Has your cancer spread to 1 or more locations?

32.8% of women in the PALOMA-3 study had cancer that spread to 1 location; 28% had cancer that spread to 2 locations; and 38.6% had cancer that spread to 3 or more locations.

Has your cancer spread to your organs?

60% of women in the PALOMA-3 study had cancer that spread to their organs.

Has your cancer spread to your bones?

23% of women in the PALOMA-3 study had cancer that spread to their bones.

If you answered “Yes” to any of the above questions, you may have something in common with the women in the PALOMA-3 study. Talk to your doctor to understand what this may mean for your treatment journey.

*Patients studied in PALOMA-3 consisted of 521 women with advanced or metastatic breast cancer who had disease progression on or after previous endocrine therapy.

User responses are not saved, collected, or used for any marketing or promotional purpose. Web site content is not altered in any way based on user responses.

PALOMA-3 was not designed to show how effective FASLODEX with palbociclib is for individual disease characteristics, but rather to show consistent effectiveness across all patients in the study.

You should not receive FASLODEX if you have had an allergic reaction to any of the ingredients in FASLODEX. Symptoms of an allergic reaction to FASLODEX may include itching; swelling of your face, lips, tongue, or throat; or trouble breathing.

The most common side effects observed in PALOMA-3 included infections; tiredness; nausea; decreased red blood cells, white blood cells, and/or platelets; sore mouth; headache; diarrhea; constipation; vomiting; sudden hair loss; rash; loss of appetite; and fever.

IMPORTANT SAFETY INFORMATION

  • You should not receive FASLODEX if you have had an allergic reaction to any of the ingredients in FASLODEX. Symptoms of an allergic reaction to FASLODEX may include: itching; swelling of your face, lips, tongue, or throat; trouble breathing
  • Before receiving FASLODEX, tell your healthcare provider about all of your medical conditions, including if you:

  • Have a low level of platelets in your blood or bleed easily. Especially tell your healthcare provider if you take a blood thinner medicine (anticoagulants)
  • Have liver problems
  • Are pregnant or plan to become pregnant, as FASLODEX can harm your unborn baby. Females who are able to become pregnant should use effective birth control during treatment with FASLODEX and for one year after the last dose. Tell your healthcare provider right away if you become pregnant or think you are pregnant while on FASLODEX
  • Are breast-feeding or plan to breast-feed. It is not known if FASLODEX passes into breast milk. Do not breast-feed during treatment with FASLODEX and for one year after the last dose. Talk to your healthcare provider about the best way to feed your baby during this time
  • FASLODEX is administered as a shot into the muscle of your buttock.

    FASLODEX may cause injection site related nerve damage. Call your healthcare provider if you develop any of the following symptoms in your legs following a FASLODEX injection: numbness; tingling; weakness.

    The most common side effects of FASLODEX include: injection site pain; nausea; muscle, joint, and bone pain; headache; tiredness; hot flashes; vomiting; loss of appetite; weakness; cough; shortness of breath, constipation; and increased liver enzymes.

Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with FASLODEX. For more information, ask your healthcare provider or pharmacist.

Approved Uses for FASLODEX

FASLODEX is a prescription medicine used to treat:

  • hormone receptor (HR)-positive breast cancer in women who have gone through menopause whose disease has spread after treatment with antiestrogen medicine, OR
  • HR-positive, human epidermal growth factor receptor 2 (HER2)‐negative breast cancer whose disease has spread to other parts of the body (metastatic) in combination with palbociclib in women with disease progression after hormonal therapy
  • When FASLODEX is used in combination with palbociclib, please also see the palbociclib Patient Information.

Please see FASLODEX Prescribing Information with Patient Information.

 
 
Read More

IMPORTANT SAFETY INFORMATION

  • You should not receive FASLODEX if you have had an allergic reaction to any of the ingredients in FASLODEX. Symptoms of an allergic reaction to FASLODEX may include: itching; swelling of your face, lips, tongue, or throat; trouble breathing
  • Before receiving FASLODEX, tell your healthcare provider about all of your medical conditions, including if you:

  • Have a low level of platelets in your blood or bleed easily. Especially tell your healthcare provider if you take a blood thinner medicine (anticoagulants)
  • Have liver problems
  • Are pregnant or plan to become pregnant, as FASLODEX can harm your unborn baby. Females who are able to become pregnant should use effective birth control during treatment with FASLODEX and for one year after the last dose. Tell your healthcare provider right away if you become pregnant or think you are pregnant while on FASLODEX
  • Are breast-feeding or plan to breast-feed. It is not known if FASLODEX passes into breast milk. Do not breast-feed during treatment with FASLODEX and for one year after the last dose. Talk to your healthcare provider about the best way to feed your baby during this time
  • FASLODEX is administered as a shot into the muscle of your buttock.

    FASLODEX may cause injection site related nerve damage. Call your healthcare provider if you develop any of the following symptoms in your legs following a FASLODEX injection: numbness; tingling; weakness.

    The most common side effects of FASLODEX include: injection site pain; nausea; muscle, joint, and bone pain; headache; tiredness; hot flashes; vomiting; loss of appetite; weakness; cough; shortness of breath, constipation; and increased liver enzymes.

Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with FASLODEX. For more information, ask your healthcare provider or pharmacist.

Approved Uses for FASLODEX

FASLODEX is a prescription medicine used to treat:

  • hormone receptor (HR)-positive breast cancer in women who have gone through menopause whose disease has spread after treatment with antiestrogen medicine, OR
  • HR-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer whose disease has spread to other parts of the body (metastatic) in combination with palbociclib in women with disease progression after hormonal therapy
  • When FASLODEX is used in combination with palbociclib, please also see the palbociclib Patient Information.